Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to -$44.5 million.

  • Coherus Oncology's Profit After Tax rose 647.49% to -$44.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $394.5 million, marking a year-over-year increase of 59791.61%. This contributed to the annual value of $28.5 million for FY2024, which is 11198.32% up from last year.
  • As of Q3 2025, Coherus Oncology's Profit After Tax stood at -$44.5 million, which was up 647.49% from $297.8 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Profit After Tax high stood at $297.8 million for Q2 2025, and its period low was -$172.9 million during Q1 2021.
  • For the 5-year period, Coherus Oncology's Profit After Tax averaged around -$22.2 million, with its median value being -$47.6 million (2024).
  • Its Profit After Tax has fluctuated over the past 5 years, first tumbled by 58618.86% in 2021, then skyrocketed by 64286.52% in 2025.
  • Over the past 5 years, Coherus Oncology's Profit After Tax (Quarter) stood at -$45.7 million in 2021, then decreased by 28.75% to -$58.9 million in 2022, then plummeted by 35.3% to -$79.7 million in 2023, then soared by 348.34% to $197.8 million in 2024, then plummeted by 122.51% to -$44.5 million in 2025.
  • Its Profit After Tax stands at -$44.5 million for Q3 2025, versus $297.8 million for Q2 2025 and -$56.6 million for Q1 2025.